RB1 and cancer: In particular, RB1 knockdown has been shown to enhance the sensitivity to cell death induced by different anticancer agents, such as DNA-damaging and microtubule interfering agents, in cells from several cancer types, including lymphoma, breast, lung, and prostate cancer, and glioblastoma [46–50].